Oral composition
Hinokitiol and copper chlorophyllin metal salts in oral compositions inhibit gingipain produced by Porphyromonas gingivalis with fimA genotype type II or IV, addressing periodontal disease progression and treatment.
Patent Information
- Application Number
- JP2024163795
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-28
AI Technical Summary
Porphyromonas gingivalis bacteria, particularly those with fimA genotype type II or IV, produce gingipain which contributes to periodontal disease progression by damaging epithelial cells and suppressing the immune system, leading to dysbiosis of oral flora and intractable periodontal disease.
The use of hinokitiol and/or copper chlorophyllin metal salts in oral compositions effectively inhibits gingipain produced by P.g bacteria with fimA genotype type II or IV.
The oral composition efficiently suppresses gingipain activity, potentially preventing and treating periodontal disease by inhibiting the protease activity of these bacteria, especially targeting the most pathogenic fimA genotype type II strains.
Smart Images

Figure 2024166418000001 
Figure 2024166418000002 
Figure 2024166418000003
Abstract
Description
[Technical field]
[0001] The present disclosure relates to an oral composition that is effective against Porphyromonas gingivalis (Pg bacteria) having a fimA genotype of type II. The contents of all documents described in this specification are incorporated herein by reference. [Background technology]
[0002] Porphyromonas gingivalis (Pg) is a periodontal disease bacterium with strong periodontal pathogenicity. Gingipain is known as a representative pathogenic factor produced by Pg. Gingipain is a type of protease, and there are Lys-gingipain (Kgp) and Arg-gingipain (Rgp) with different peptide cleavage site specificities. These interact with each other to cause destruction of the bonds between gingival epithelial cells, damage to the epithelial cells themselves and / or inhibition of their growth, and ultimately destruction of the epithelial barrier and inhibition of repair. Gingipain is also said to have the effect of suppressing phagocytosis by phagocytes and digestion within cells, as well as the effect of destroying the complement system and helping to invade epithelial cells, and is therefore involved in the evasion of Pg from the immune system. Furthermore, it has recently been reported that the suppressive effect of gingipain on the immune system leads to dysbiosis of the oral bacterial flora, and these actions of gingipain lead to the progression and intractability of periodontal disease.
[0003] In recent years, attention has been focused on the gene fimA, which encodes fimbrillin, a cilia-forming subunit of Pg bacteria. There are six different genotypes (fimA types) of fimA due to differences in the nucleic acid sequence structure, and it has been suggested that there is a strong correlation between the severity of periodontal disease and type II or IV fimA bacteria of P. gingivalis (particularly type II fimA bacteria) (Non-Patent Documents 1 and 2). Furthermore, these six different genotypes (fimA types) can be easily identified, for example, by using PCR primers specific to each genotype (Non-Patent Document 2). Furthermore, the strength of virulence of the fimA types and the genotype of gingipains have been reported. It has also been pointed out that there is a correlation between the above and the GABAergic encephalopathy (Non-Patent Document 3). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Publication No. 2016 / 104524 [Non-patent literature]
[0005] [Non-Patent Document 1] "Relationship between cilia of Porphyromonas gingivalis and periodontal pathogenicity" Journal of the Japanese Society of Periodontology 45(4):357-363,2003 [Non-Patent Document 2] "Distribution of periodontal disease-related bacteria using genetic testing methods" Japanese Journal of Clinical Microbiology Vol. 28 No. 4 2018 [Non-Patent Document 3] Journal of Oral Microbiology 2015, 7: 29124 Summary of the Invention [Problem to be solved by the invention]
[0006] Therefore, if gingipain produced by Pg bacteria with fimA genotypes II or IV can be efficiently inhibited, it is believed that periodontal disease can be prevented and / or treated (especially the progression of periodontal disease) particularly efficiently. [Means for solving the problem]
[0007] The present inventors have found that by using hinokitiol and / or copper chlorophyllin metal salt, gingipain produced by Pg bacteria having fimA genotypes II and IV is particularly efficiently suppressed. I discovered I could control it.
[0008] The present disclosure includes, for example, the subject matter described in the following sections: Section 1. Contains hinokitiol and / or copper chlorophyllin metal salt, For people with oral Porphyromonas gingivalis (Pg) of fimA genotype II or IV, Anti-periodontal oral compositions. Section 2. Contains hinokitiol and / or copper chlorophyllin metal salt, For people with oral Porphyromonas gingivalis (Pg) of fimA genotype II or IV, An oral composition for inhibiting the protease produced by the Pg bacteria. Section 3. Item 3. The oral composition according to item 1 or 2, which contains hinokitiol and copper chlorophyllin metal salt. Section 4. Item 4. The oral composition according to any one of Items 1 to 3, for a person who has Pg bacteria of fimA genotype II in the oral cavity. Section 5. Item 5. The oral composition according to any one of Items 1 to 4, for a person in whom the fimA genotype and type II Pg bacteria are most prevalent in the oral cavity. Effect of the Invention
[0009] Provided is a composition for oral cavity that can efficiently inhibit gingipain produced by Pg bacteria having fimA genotype II or IV. [Brief description of the drawings]
[0010] [Figure 1a] The results of an investigation into whether various antibacterial and anti-inflammatory ingredients are capable of suppressing gingipain activity in Pg bacteria (type IV fimA strain) are shown below. [Figure 1b] The results of an investigation into whether various antibacterial and anti-inflammatory ingredients are capable of suppressing gingipain activity in Pg bacteria (type IV fimA strain) are shown below. [Figure 2a] The results of an investigation into whether sodium copper chlorophyllin can inhibit the gingipain activity produced by each strain of Pg bacteria (type II fimA strain or type IV fimA strain) are shown. [Figure 2b] The results of an investigation into whether hinokitiol can inhibit the gingipain activity produced by each strain of Pg bacteria (type II fimA strain or type IV fimA strain) are shown. [Figure 3a] 1 shows the results of investigating the inhibitory effect of sodium copper chlorophyllin and hinokitiol on the gingipain activity of Pg bacteria (type II fimA strain) when used in combination. [Figure 3b] 1 shows the results of investigating the inhibitory effect of sodium copper chlorophyllin and isopropyl methylphenol on gingipain activity in Pg bacteria (type II fimA strain) when used in combination. [Figure 3c] 1 shows the results of investigating the inhibitory effect of copper chlorophyllin sodium and chlorhexidine hydrochloride on the gingipain activity of Pg bacteria (type II fimA strain) when used in combination. [Figure 3d] 1 shows the results of investigating the inhibitory effect of a combination of sodium copper chlorophyllin and cetylpyridinium chloride on the gingipain activity of Pg bacteria (type II fimA strain). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Each embodiment included in the present disclosure will be described in more detail below. The present disclosure preferably includes, but is not limited to, compositions for use in the cavity and uses thereof, and includes all that is disclosed in the present specification and that can be recognized by a person skilled in the art.
[0012] The oral composition included in the present disclosure contains hinokitiol and / or copper chlorophyllin metal salt. As the copper chlorophyllin metal salt, copper chlorophyllin alkali metal salt is preferable, and among them, copper chlorophyllin sodium or copper chlorophyllin potassium is preferable. In addition, the oral composition may be called the oral composition of the present disclosure.
[0013] The oral composition of the present disclosure can be preferably used as an anti-periodontal disease oral composition for a person who has Porphyromonas gingivalis (Pg bacteria) of fimA genotype II or IV in the oral cavity. More specifically, the composition can be preferably used for preventing and / or treating periodontal disease, or inhibiting the progression of periodontal disease, for the person.
[0014] Furthermore, as described above, the oral composition of the present disclosure can efficiently suppress gingipains produced by Pg bacteria having fimA genotypes II or IV, and therefore can also be referred to as an oral composition for inhibiting proteases produced by said Pg bacteria.
[0015] In addition, there are six types of fimA genotypes of Pg bacteria, including types I, Ib, II, III, IV, and V, and some people have Pg bacteria of multiple fimA genotypes. Among these, type II is considered to be the most pathogenic. Therefore, the oral composition of the present disclosure can be preferably used for people who have the most fimA genotype II Pg bacteria in their oral cavity.
[0016] Among these oral compositions, for example, an oral composition containing hinokitiol and copper chlorophyllin metal salt is particularly preferred because the combination of hinokitiol and copper chlorophyllin metal salt exhibits a particularly excellent effect of inhibiting gingipains produced by Pg bacteria having fimA genotypes II and IV.
[0017] The amount of hinokitiol contained in the oral cavity composition is preferably, for example, 0.003% by mass or more. There is no particular upper limit, but an example of the upper limit is 0.2% by mass. The amount range is preferably, for example, about 0.003 to 0.2% by mass. The upper or lower limit of the range may be, for example, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, or 0.19% by mass. For example, it may be about 0.004 to 0.15% by mass or about 0.005 to 0.1% by mass.
[0018] The amount of copper chlorophyllin metal salt contained in the oral cavity composition is preferably, for example, 0.003% by mass or more. There is no particular upper limit, but an example of the upper limit is 0.2% by mass. The amount range is preferably, for example, about 0.003 to 0.2% by mass. The upper or lower limit of the range may be, for example, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, or 0.19% by mass. For example, it may be about 0.004 to 0.15% by mass or about 0.005 to 0.1% by mass.
[0019] The oral composition may be a solid composition or a liquid composition. The oral composition may be used, for example, as a pharmaceutical or quasi-drug. The form of the composition is not particularly limited. However, it can be made into, for example, an ointment, paste, gel, liquid, spray, mouthwash, liquid dentifrice, toothpaste, gum, etc. (dosage form) in accordance with a conventional method. Among these, mouthwash, liquid dentifrice, toothpaste, ointment, paste, liquid, and gel forms are preferred.
[0020] The oral composition may further contain one or more optional components that can be blended in the oral composition, provided that the above-mentioned effects are not impaired.
[0021] For example, the surfactant may be a nonionic surfactant, an anionic surfactant, or an amphoteric surfactant.Specific examples of nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ethers with a polyoxyethylene addition coefficient of 8 to 10 and an alkyl group with 13 to 15 carbon atoms; polyoxyethylene alkylphenyl ethers with a polyoxyethylene addition coefficient of 10 to 18 and an alkyl group with 9 carbon atoms; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan; and the like.Examples of anionic surfactants include sulfate ester salts such as sodium lauryl sulfate and polyoxyethylene lauryl ether sodium sulfate; sulfosuccinate salts such as sodium lauryl sulfosuccinate and polyoxyethylene lauryl ether sodium sulfosuccinate; acylamino acid salts such as sodium cocoyl sarcosine and sodium lauroyl methyl alanine; and sodium cocoyl methyl taurine. Examples of amphoteric surfactants include acetate betaine type surfactants such as lauryl dimethylamino acetate betaine and coconut oil fatty acid amidopropyl dimethylamino acetate betaine; imidazoline type surfactants such as N-cocoyl-N-carboxymethyl-N-hydroxyethyl ethylenediamine sodium; and amino acid type surfactants such as N-lauryl diaminoethyl glycine. These surfactants can be blended alone or in combination of two or more. The blending amount is usually 0.1 to 5% by mass based on the total amount of the composition.
[0022] In addition, as the flavoring agent, for example, menthol, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decyl alcohol, citronellol, α-terpineol, methyl acetate, citronenyl acetate, methyl eugenol, cineole, linalool, ethyl linalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, pimento oil, d-camphor, d-borneol, fennel oil, cinnamon oil, cinnamaldehyde, peppermint oil, vanillin, etc. can be used. These can be blended alone or in combination of two or more kinds, for example, in an amount of 0.001 to 1.5% by mass based on the total amount of the composition.
[0023] In addition, examples of sweeteners that can be used include saccharin sodium, acesulfame potassium, stevioside, neohesperidyl dihydrochalcone, perillartine, thaumatin, aspartyl phenylalanyl methyl ester, p-methoxycinnamic aldehyde, etc. These can be blended in an amount of, for example, 0.01 to 1% by mass based on the total amount of the composition.
[0024] Furthermore, as a wetting agent, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol, etc. can be blended alone or in combination of two or more kinds.
[0025] Preservatives: methylparaben, ethylparaben, propylparaben, butylparaben Parabens such as benzoate, sodium benzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride, etc. can also be added.
[0026] As coloring agents, legal pigments such as Blue No. 1, Yellow No. 4, Red No. 202, Green No. 3, mineral pigments such as ultramarine, enhanced ultramarine, and Prussian blue, titanium oxide, etc. may be blended.
[0027] As a pH adjuster, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically possible salts thereof, sodium hydroxide, etc. may be blended. These may be blended alone or in combination of two or more kinds so that the pH of the composition is in the range of 4 to 8, preferably 5 to 7. The blending amount of the pH adjuster may be, for example, 0.01 to 2% by weight.
[0028] In addition, within the scope that does not impair the effect, the oral composition may further contain, as an active ingredient, vitamin E such as dl-α-tocopherol acetate, tocopherol succinate, or tocopherol nicotinate, a cationic bactericide such as cetylpyridinium chloride, an anionic bactericide such as sodium lauroyl sarcosine, an amphoteric bactericide such as dodecyldiaminoethylglycine, a nonionic bactericide such as triclosan or isopropylmethylphenol, an enzyme such as dextranase, amylase, protease, mutanase, lysozyme, or a lytic enzyme (retic enzyme), Alkaline metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate, fluorides such as sodium fluoride and stannous fluoride, tranexamic acid, epsilon aminocaproic acid, aluminum chlorohydroxyl allantoin, dihydrocholesterol, glycyrrhetinic acid, glycerophosphate, chlorophyll, sodium chloride, callopeptide, allantoin, carbazochrome, hinokitiol, potassium nitrate, palatinit, etc. can be blended alone or in combination of two or more.
[0029] Furthermore, it is also possible to add, as a base, alcohols, silicone, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, plastibase, and the like.
[0030] The oral composition can be prepared by a known method or a method easily derived from a known method, for example, by appropriately mixing hinokitiol and / or copper chlorophyllin metal salt and other components as necessary.
[0031] In addition, in this specification, the term "comprising" includes "consisting essentially of" and "consisting of." In addition, the present disclosure includes all arbitrary combinations of the constituent elements described in this specification.
[0032] In addition, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present disclosure above may be combined in any way to specify the subject matter included in the present disclosure. In other words, the present disclosure includes all subject matter consisting of all combinations of each combinable characteristic described in this specification. EXAMPLES
[0033] The following examples are provided to more specifically describe the embodiments of the present disclosure, but the embodiments of the present disclosure are not limited to the following examples. Note that the amounts of various components examined below may be indicated in terms of concentration (ppm), but although the mass of the solution used per ml is slightly greater than 1 g, it can be roughly converted to 1000 ppm = 0.1 mass %.
[0034] Search for components that inhibit gingipain activity The inhibitory effect of various antibacterial and anti-inflammatory ingredients on gingipain activity was examined. The ingredients examined were sodium copper chlorophyllin, hinokitiol, isopropylmethylphenol (IPMP), cetylpyridinium chloride (CPC), chlorhexidine hydrochloride (CHX), dipotassium glycyrrhizinate (GK2), β-glycyrrhetinic acid, tranexamic acid, allantoin, aminocaproic acid, vitamin B6 (VB6), and vitamin E acetate (VEA; also known as dl-α-tocopherol acetate). The Pg bacteria examined were type IV fimA strain W83.
[0035] Pg bacteria (P. gingivalis W83) were cultured in GAM medium and the absorbance (OD(600)) was adjusted to 1.0. The bacterial solution was centrifuged at 10,000 rpm, and the supernatant was collected. The collected supernatant contained gingipain. 200 μL of a solution in which various test components were adjusted to various concentrations with 10% DMSO was mixed with 20 μL of the above supernatant and left for 3 minutes. After 3 minutes, it was mixed with a gingipain substrate (Z-Phe-Arg-MCA; Peptide Institute, Inc.) diluted 100-fold with PBS, and left to stand at 37°C for 1 hour in the dark. Z-Phe-Arg-MCA is Benzyloxycarbonyl-L-phenylalanyl-L-arginine 4-methylcoumaryl-7-amide (Hydrochloride Form), and is cleaved by Arg-gingipain (Rgp) activity. It is a reagent that emits fluorescence when exposed to light. After 1 hour, the fluorescence intensity (excitation light: 380 nm, emission light: 440 nm) was measured using a fluorescence plate reader (Gemini XPS). The fluorescence intensity at a test component concentration of 0 μg / mL was converted to 100%, and the gingipain activity when the test component was treated at each concentration was calculated. Note that the test was performed with n=2 for each concentration, and the calculated value was the average. The smaller the calculated value, the more suppressed the gingipain activity. The results are shown in Figure 1a and Figure 1b.
[0036] Of the various components examined, it was found that only hinokitiol and sodium copper chlorophyllin had the effect of suppressing gingipain activity.
[0037] Inhibitory effect of hinokitiol and copper chlorophyllin sodium on gingipain activity In addition to W83, OMZ314, a type II fimA strain, and W50, a type IV fimA strain, were used as Pg strains, and Z-His-Glu-Lys-MCA (Peptide Institute, Inc.) as well as Z-Phe-Arg-MCA were used as gingipain substrates to investigate the inhibitory effects of hinokitiol and sodium copper chlorophyllin on gingipain activity in the same manner as above. Z-His-Glu-Lys-MCA is benzyloxycarbonyl-L-histidyl-L-glutamyl-L-lysine 4-methylcoumaryl-7-amide (hydrochloride form), which is cleaved by Lys-gingipain (Kgp) activity to emit fluorescence.
[0038] The results when using sodium copper chlorophyllin are shown in Figure 2a, and the results when using hinokitiol are shown in Figure 2b. In these figures, the horizontal axis indicates the concentration (ppm) of sodium copper chlorophyllin or hinokitiol.
[0039] Examination of the effect of combining antibacterial ingredients in suppressing gingipain activity The inhibitory effect of various bactericidal components on the activity of gingipain produced by Pg bacteria (OMZ314, a type II fimA strain) was examined. Specifically, the inhibitory effect of sodium copper chlorophyllin combined with hinokitiol, isopropylmethylphenol (IPMP), chlorhexidine hydrochloride (CHX), or cetylpyridinium chloride (CPC) was examined in the same manner as above. The results of the combination of sodium copper chlorophyllin and hinokitiol are shown in Figure 3a, the results of the combination of sodium copper chlorophyllin and IPMP in Figure 3b, the results of the combination of sodium copper chlorophyllin and CHX hydrochloride in Figure 3c, and the results of the combination of sodium copper chlorophyllin and CPC in Figure 3d. The results when both were combined are shown in Figure 3d. In these figures, the vertical axis indicates gingipain (Rgp) activity (%). The concentration of each bactericidal component is shown in mass %. Furthermore, "copper chloro" refers to sodium copper chlorophyllin.
[0040] When the bactericidal components other than hinokitiol were used in combination with sodium copper chlorophyllin, they only showed the same inhibitory effect on gingipain activity as when sodium copper chlorophyllin was used alone, or even showed a lower inhibitory effect on gingipain activity than when sodium copper chlorophyllin was used alone. On the other hand, when sodium copper chlorophyllin was used in combination with hinokitiol, a particularly excellent inhibitory effect on gingipain activity was obtained.
Claims
[Claim 1] A composition comprising copper chlorophyllin metal salt. For people with oral Porphyromonas gingivalis (P. gingivalis) of fimA genotype II or IV, Anti-periodontal oral compositions.
Citation Information
Patent Citations
Agent for enhancing adherens junction function
WO2016104524A1
